Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Acute Myeloid Leukemia in Remission, Acute Myeloid Leukemia (AML), Leukemic Dendritic Cell Vaccination
- Main trialPhase 2
- “Phase II study to evaluate safety and efficacy of DCP-001 in patients with AML in CR, and with presence of MRD”In the company’s words, NCT03697707 on ClinicalTrials.gov
Other drugs for Acute Myeloid Leukemia in Remission
- GLSI-100Greenwich LifeSciences, Inc. · Phase 3
- TisagenlecleucelNovartis · Phase 2
- BlinatumomabAmgen · Phase 1/2
- Cemacabtagene ansegedleucelAllogene Therapeutics · Phase 2
- IvonescimabAkeso · Summit Therapeutics · Phase 2
- INCA33890Incyte Corporation · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Unknown | Mar 2023 | Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia | |
| Phase 1/2Completed | Feb 2013 | Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026